Literature DB >> 8699334

Albumin binding and time action of acylated insulins in various species.

P Kurtzhals1, S Havelund, I Jonassen, B Kiehr, U Ribel, J Markussen.   

Abstract

Insulins acylated with fatty acids at the epsilon-amino group of LysB29 constitute a new class of insulin analogs, which are prolonged-acting due to albumin binding. In the present study it is shown that the affinity of fatty acid acylated insulins for albumin varies considerably (> 50-fold) among species. The relative affinities of acylated insulin for albumin in human, pig, and rabbit serum are about 1:1:5:35. The several fold higher binding affinity in rabbit serum than in pig serum is reflected in a relatively more protracted effect after sc injection in rabbits than in pigs. Due to the similar binding affinities in pig serum and human serum, the pig model should provide a useful estimate of the degree of protraction of acylated insulin in humans. The results emphasize that species differences in ligand binding can be of major importance in the preclinical evaluation of highly albumin bound drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699334     DOI: 10.1021/js950412j

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

Review 1.  Special considerations with insulin therapy in older adults with diabetes mellitus.

Authors:  Arshag D Mooradian
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Simulations of a membrane-anchored peptide: structure, dynamics, and influence on bilayer properties.

Authors:  Morten Ø Jensen; Ole G Mouritsen; Gunther H Peters
Journal:  Biophys J       Date:  2004-06       Impact factor: 4.033

Review 3.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

4.  Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.

Authors:  Michael Højby Rasmussen; Jurgita Janukonyté; Marianne Klose; Djordje Marina; Mette Tanvig; Lene F Nielsen; Charlotte Höybye; Marianne Andersen; Ulla Feldt-Rasmussen; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2016-01-04       Impact factor: 5.958

Review 5.  A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.

Authors:  Ralph Oiknine; Marla Bernbaum; Arshag D Mooradian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Tissue selectivity of insulin detemir action in vivo.

Authors:  A M Hennige; T Sartorius; O Tschritter; H Preissl; A Fritsche; P Ruth; H-U Häring
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

7.  Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system.

Authors:  M C Moore; M S Smith; M K Turney; S Boysen; P E Williams
Journal:  Diabetes Obes Metab       Date:  2011-09       Impact factor: 6.577

8.  A novel oral vehicle for poorly soluble HSV-helicase inhibitors: PK/PD validations.

Authors:  Jianmin Duan; Francine Liard; William Paris; Michelle Lambert
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

9.  Engineering Synthetically Modified Insulin for Glucose-Responsive Diabetes Therapy.

Authors:  Matthew J Webber; Daniel G Anderson; Robert Langer
Journal:  Expert Rev Endocrinol Metab       Date:  2015-07-18

Review 10.  The role of insulin detemir in overweight type 2 diabetes management.

Authors:  Yared N Demssie; Naveed Younis; Handrean Soran
Journal:  Vasc Health Risk Manag       Date:  2009-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.